October 1, 2021
Life Sciences
  • Merck & Co. said its experimental antiviral pill to treat COVID-19 reduced the risk of hospitalization and death by nearly half in a clinical trial. The results prompted an independent monitoring board to recommend the study end early because of the promising results, though the data has not yet been published or peer reviewed. Merck and its partner, Ridgeback Biotherapeutics, said they will apply for regulatory authorization for the treatment soon, in what would be the first antiviral pill for COVID-19. (Articles here, here, here, here, and here)